Literature DB >> 18511032

Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptor?

Joep H M van Esch1, Chantal R Oosterveer, Wendy W Batenburg, Richard van Veghel, A H Jan Danser.   

Abstract

Aminopeptidases metabolize angiotensin II to angiotensin-(2-8) (=angiotensin III) and angiotensin-(3-8) (=angiotensin IV), and carboxypeptidases generate angiotensin-(1-7) from angiotensin I and II. Angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin II type 1 (AT1) receptor blockers affect the concentrations of these metabolites, and they may thus contribute to the beneficial effects of these drugs, possibly through stimulation of non-classical angiotensin AT receptors. Here, we investigated the effects of angiotensin II, angiotensin III, angiotensin IV and angiotensin-(1-7) in the rat coronary vascular bed, with or without angiotensin AT1 - or angiotensin II type 2 (AT2) receptor blockade. Results were compared to those in rat iliac arteries and abdominal aortas. Angiotensin II, angiotensin III and angiotensin IV constricted coronary arteries via angiotensin AT1 receptor stimulation, angiotensin III and angiotensin IV being approximately 20- and approximately 8000-fold less potent than angiotensin II. The angiotensin AT2 receptor antagonist PD123319 greatly enhanced the constrictor effects of angiotensin III, starting at angiotensin III concentrations in the low nanomolar range. PD123319 enhanced the angiotensin II-induced constriction at submicromolar angiotensin II concentrations only. Angiotensin-(1-7) exerted no effects in the coronary circulation, although, at micromolar concentrations, it blocked angiotensin AT1 receptor-induced constriction. Angiotensin AT2 receptor-mediated relaxation did not occur in iliac arteries and abdominal aortas, and the constrictor effects of the angiotensin metabolites in these vessels were identical to those in the coronary vascular bed. In conclusion, angiotensin AT2 receptor activation in the rat coronary vascular bed results in vasodilation, and angiotensin III rather than angiotensin II is the preferred endogenous agonist of these receptors. Angiotensin II, angiotensin III, angiotensin IV and angiotensin-(1-7) do not exert effects through non-classical angiotensin AT receptors in the rat coronary vascular bed, iliac artery or aorta.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511032     DOI: 10.1016/j.ejphar.2008.04.042

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  High-salt diet and hypertension: focus on the renin-angiotensin system.

Authors:  I Drenjančević-Perić; B Jelaković; J H Lombard; M P Kunert; A Kibel; M Gros
Journal:  Kidney Blood Press Res       Date:  2010-11-12       Impact factor: 2.687

Review 2.  Key developments in renin-angiotensin-aldosterone system inhibition.

Authors:  Bruno Sevá Pessôa; Nils van der Lubbe; Koen Verdonk; Anton J M Roks; Ewout J Hoorn; A H Jan Danser
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

3.  Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors.

Authors:  Brandon A Kemp; John F Bell; Daniele M Rottkamp; Nancy L Howell; Weijian Shao; L Gabriel Navar; Shetal H Padia; Robert M Carey
Journal:  Hypertension       Date:  2012-06-11       Impact factor: 10.190

Review 4.  Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Authors:  Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

5.  Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats.

Authors:  Shetal H Padia; Brandon A Kemp; Nancy L Howell; John J Gildea; Susanna R Keller; Robert M Carey
Journal:  Hypertension       Date:  2008-12-15       Impact factor: 10.190

6.  Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts.

Authors:  Joep H M van Esch; Florian Gembardt; Anja Sterner-Kock; Silvia Heringer-Walther; Thu H Le; Dirk Lassner; Theo Stijnen; Thomas M Coffman; Heinz-Peter Schultheiss; A H Jan Danser; Thomas Walther
Journal:  Cardiovasc Res       Date:  2010-01-12       Impact factor: 10.787

Review 7.  The intrarenal renin-angiotensin and dopaminergic systems: control of renal sodium excretion and blood pressure.

Authors:  Robert M Carey
Journal:  Hypertension       Date:  2013-03       Impact factor: 10.190

Review 8.  AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function.

Authors:  Shetal H Padia; Robert M Carey
Journal:  Pflugers Arch       Date:  2012-09-05       Impact factor: 3.657

9.  Cardioprotective effects of angiotensin III against ischemic injury via the AT2 receptor and KATP channels.

Authors:  Byung Mun Park; Shan Gao; Seung Ah Cha; Byung Hyun Park; Suhn Hee Kim
Journal:  Physiol Rep       Date:  2013-11-13

Review 10.  Revisiting the Brain Renin-Angiotensin System-Focus on Novel Therapies.

Authors:  Liwei Ren; Xifeng Lu; A H Jan Danser
Journal:  Curr Hypertens Rep       Date:  2019-04-04       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.